اكتشف أفضل عيادات وتكاليف العلاج فقدان السمع في إسبانيا 2025

الدكتور جوردي كورومينا إيزيرن هو طبيب أنف وأذن وحنجرة متميز يتمتع بخبرة مهنية تزيد عن 30 عاماً. وهو معروف بخبرته السريرية الواسعة، والتزامه باستخدام أحدث التقنيات في ممارسته، وأدواره كمعلم ومؤلف محترم. الجوائز جائزة سيزار برتران من الجمعية الإسبانية لطب الأنف والأذن والحنجرةجائزة الجمعية الكاتالونية لأمراض الرئة العضوية عضو الجمعية الإسبانية لطب الأنف والأذن والحنجرةعضو في الجمعية الكاتالونية لأمراض الرئة التعليم دكتوراه في الطب، بامتياز مع مرتبة الشرفالتدريب في مايو كلينيك في روتشستر، ومستشفى بوسطن للأطفال، ومعهد هاوس للأذن في لوس أنجلوس، ومجموعة أطباء الأذن في بياتشينزا، ومجمع مستشفيات بيروني في مونبلييه

Dr. Karin P. Q. Oomen, MD PhDConsultant ENT Surgeonwww.andsurgeons.comDate of Birth: 13 August 1977EducationBiology, University of Utrecht — Sep 1995 – Sep 1996Doctoral Degree in Medicine, University of Utrecht — Sep 1996 – Dec 2001M.D., School of Medicine, University of Utrecht — Dec 2001 – Dec 2003Junior Staff Teacher, Dept. of Anatomy, UMC Utrecht — Jun 2004 – Aug 2005Senior House Officer, ENT Surgery, UMC Utrecht — Aug 2005 – Jan 2006Residency, ENT Surgery, UMC Utrecht/Wilhelmina Children's Hospital — Feb 2006 – Feb 2011PhD, Dept. of Anatomy & ENT Surgery, University of Utrecht — Feb 2011 – May 2011Thesis: Anatomical and clinical appraisal of the pterygopalatine ganglion. Defended: 27 May 2011CertificationsECFMG Certification — 1 May 2012Step I: 203/84Step IIa – Clinical Knowledge: 223/80Step IIb – Clinical Skills: PassFellowshipPaediatric Otolaryngology, Weill Cornell Medical College, New York, USA — Aug 2011 – Aug 2013Mentors: Dr. Robert F. Ward, Dr. Vikash K. ModiProfessional ExperienceCurrent Positions (since 2022)Consultant ENT Surgeon & Owner, ANDSURGEONS, AndorraConsultant ENT Surgeon, Clínica Omega Zeta & Clínica SOM Salut, AndorraConsultant ENT Surgeon, Doctus (La Seu d'Urgell), Avantmedic (Lleida), Centro Medico Teknon (Barcelona), SpainLocum Consultant ENT Surgeon, Medinet, Portland Clinical, Imperial College London (Honorary Contract)Previous RolesPaediatric Otolaryngologist, UMC Utrecht/Wilhelmina Children’s Hospital — Feb 2014 – Feb 2016Specialized in voice, airway, cleft palate, 22q11, and laryngotracheal surgeryResearcher, Access to Medicine Foundation, Amersfoort — Feb 2017 – Apr 2017Lead author of publication on cancer care access in LMICsConsultant ENT Surgeon, Elkerliek Hospital, Helmond, NL — May – Jun 2017Consultant ENT Surgeon, Queen Alexandra Hospital, Portsmouth, UK — Sep 2017 – Dec 2020LicensureUnited Kingdom: GMC #7511829 – Fully Registered, Specialist RegistrationNetherlands: BIG #49061371701 – Physician (since Dec 2023)Netherlands: RGS #1910932 – Otolaryngologist (since Feb 2011)Spain: COMB #65907 (Barcelona)Andorra: RPS #03255, Collegiat #913LanguagesDutch: NativeEnglish: Full Professional ProficiencySpanish, German: Professional Working ProficiencyFrench: Limited Working ProficiencyIdentification NumbersNL Social Security: 170621303UK NI Number: SZ758509BSpain NIE: Z1396887-XAndorra NIA: 387493RMedical MissionsCleft lip and palate repair, Antigua, Guatemala — MMFC — Jun 2012PublicationsSelected from 26 total; full list available on request1. Oomen KP, et al. Effect of adenotonsillectomy on middle ear status in children. Laryngoscope 2005.2. Oomen KP, et al. Sluder’s neuralgia: a trigeminal autonomic cephalalgia? Cephalalgia 2010.3. Oomen KPQ, et al. A previously undescribed branch of the pterygopalatine ganglion. Am J Rhinol Allergy 2011.

CURRICULUM VITAEVOLKERT B. WREESMANN MD PhDConsultant OtolaryngologistOncologic Head and Neck SurgeonThyroid and Parathyroid SurgeonFacial Plastic Surgeon Principal PositionsCentro Medico Teknon, Barcelona, SpainChairman, Department of Otolaryngology-Head and Neck SurgeryJuly 1st 2024 – present Juaneda, Ciutadella Menorca, SpainConsultant Otolaryngologist-Head and Neck SurgeonJanuary 2025 – present Avantmedic, Lleida, SpainConsultant Otolaryngologist-Head and Neck SurgeonJuly 1st 2024 – present Clinica Omega Zeta, AndorraConsultant Otolaryngologist-Head and Neck SurgeonMarch 1st 2022 – present University Hospitals Dorset NHS Foundation TrustConsultant Otolaryngologist-Head and Neck SurgeonAugust 1st 2021 – October 1st 2023 Oxford University Hospitals NHS Foundation TrustHonorary Consultant Otolaryngologist-Head and Neck SurgeonMay 1st 2021 – April 30th 2024 Portsmouth Hospitals University NHS Trust, Portsmouth, UKConsultant Otolaryngologist-Head and Neck SurgeonJuly 18th 2016 – April 30th 2021 Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UKConsultant Otolaryngologist-Head and Neck SurgeonNovember 7th 2015 – May 31st 2016 Heart of England NHS Trust, Birmingham, UKConsultant Otolaryngologist-Head and Neck SurgeonMarch 1st 2015 – October 31st 2015 University Medical Center Utrecht, NetherlandsConsultant Otolaryngologist-Head and Neck SurgeonNovember 1st 2013 – June 1st 2014 MembershipsAmerican Head and Neck Society – MemberNetherlands Academy of Otolaryngology - Member Professional LicencesUnited KingdomGMC CertificationFully Registered Medical Practitioner with Specialist Registration with a License to PracticeRegistered: 02/02/2015GMC # 7499626 United States of AmericaNew York State Department of HealthNew York State Education DepartmentRegistered: July 2011License# P80949Physician NetherlandsDutch Ministry of Health (BIG Registration)BIG Registered: 22-06-2005BIG #19063373601Physician Dutch Specialist Board (RGS)RGS registered: 01-02-2011RGS #1911979Otolaryngology-Head and Neck Surgeon SpainCollegi de Metges de BarcelonaCOMB: 63638 AndorraCollegi de Metges d’AndorraRPS: 03098COMA: 876EducationMemorial Sloan-Kettering Cancer CenterSurgical Fellowship, Head and Neck SurgeryNew York, New York, USAAugust 1st 2011 - July 31st 2013600 bed dedicated cancer centerPerformed 1200 major oncologic head and neck resections in 2 years United States of America ECFMG CertificationUnited States Medical Licensing Examination (USMLE)Certification: June 22nd, 2010Scores:    Step I: 244/99    Step IIa-Clinical knowledge: 227/94   Step IIb-Clinical Skills: PASSED   Step III: 206/85 Netherlands Cancer InstituteSurgical Fellowship, Head and Neck SurgeryAmsterdam, The NetherlandsFebruary 1st 2011 - July 31st 2011Specialized Head and Neck Cancer Surgery Department200 bed hospital Amsterdam University Medical Center/Netherlands Cancer InstituteResidency Training, Otolaryngology-Head and Neck SurgeryAmsterdam, the NetherlandsFebruary 1st 2006 – January 31st 2011 University of Amsterdam School of MedicineMedical Doctor (MD)Amsterdam, the NetherlandsDecember 2002 - January 28th 2005 University of AmsterdamDoctor of Philosophy (PhD), Molecular BiologyAmsterdam, the NetherlandsThesis title: Molecular-cytogenetic characterization of head and neck cancerDecember 2nd, 2004 Erasmus University School of MedicineDoctoral Degree in MedicineRotterdam, the NetherlandsSeptember 1994 - November 17th, 1998 Research TrainingMemorial Sloan-Kettering Cancer CenterLaboratory of Epithelial Cancer Biology, Head and Neck Service, Department of Surgery, New York, New York, USAResearch Fellowship in Molecular OncologySupervisors: Dr. Bhuvanesh Singh MD, PhD and Dr. Jatin P. Shah, MD, FACSMarch 1st 1999 - September 30st 2002 University of California San Francisco (UCSF)Department of Otolaryngology-Head and Neck Surgery, San Francisco, California, USAPost-doctoral Research Fellowship in Head and Neck OncologySupervisors: Dr. Steven Wang MD And Prof David Eisele MDFebruary 2005 - January 2006 Academic ActivitiesUniversity of Amsterdam Doctorate Examination Committee memberSeptember 17th, 2013 - PhD Candidate: Dr. I.J. Nixon (United Kingdom)October 17th 2014 - PhD Candidate: Dr. J. Pramana (Netherlands)November 17th 2015 - PhD candidate: Dr. H. van Monsjou (Netherlands)December 11th 2018 - PhD Candidate: Dr. Tihana Ibrahimpasic (United States)January 18th, 2021 - PhD Candidate: Dr. Laura Wang (Australia)June 2nd, 2021 - PhD Candidate: Dr. Caroline Verhagen (Netherlands) Conference FacultyAdvanced Laryngopharyngeal Cancer: Functional Preservation and Rehabilitation, Portsmouth, June 25th - 26th, 2020 (postponed due to COVID) - ChairmanFunctional Preservation and Rehabilitation after Treatment for Advanced Laryngeal Cancer, Portsmouth, March 14th - 15th, 2019 - ChairmanPortsmouth Parathyroid Conference, Portsmouth, December 14th 2018 – Chairman Editorial RolesEuropean Journal of Surgical OncologyAssociate EditorJanuary 1st 2023 – present European Journal of Surgical OncologyGuest EditorMarch issue 2018, Volume 44, Issue 3, p275-378 - Special issue on thyroid cancer management Journal of Oral Pathology and MedicineGuest EditorNovember issue 2021, Volume 51, Issue 10 - Special issue on vascular malformations and tumors of the head and neck Scientific Journal ReviewerOral Oncology, European Journal of Surgical Oncology, Journal of Surgical Oncology, Head and Neck, International Journal of Cancer Scientific Project and Grant ReviewerNetherlands: Dutch Cancer SocietyFrance: Institute National du Cancer AwardsNew York Head and Neck SocietyAnnual Meeting, New York, NY, March 2002Title of study presented: “MUC1 is a target if 1q amplification and pertains a grave clinical prognosis in papillary thyroid cancer” Invited LecturesEuropean Society of Surgical Oncology meeting, Krakow, 2016Barcelona Society of Neurosurgery, Annual Meeting, Baqueira, Spain, February, 2017University of Edinburgh, Department of Otolaryngology Academic Conference, March 17th 2017Medilex: Performance of Medical Specialists, Zeist, Netherlands, November 9th 2017Medilex: Performance of Medical Specialists, Driebergen, Netherlands, October 11th 2017Wessex Head and Neck and Thyroid Network Education Day, May 3rd, 2017Portsmouth Parathyroid Conference, Portsmouth, UK, December 14th 2018Global Post-laryngectomy Rehabilitation Academy, Portsmouth, UK, March 14th 2019Health Care Quality Conference, Beverwijk, Netherlands, March 25th, 2019 Published Research ReportsThe growing precision of diagnostic pathways in thyroid nodule evaluation. Bekker J, Wreesmann VB. Eur J Surg Oncol. 2025 Jan;51(1):109374. Special issue: Management of vascular tumors and malformations of the head and neck. Oomen KPQ, Brennan PA, Wreesmann VB. J Oral Pathol Med. 2022 Nov;51(10):829. Angiosarcomas of the head and neck: Impact of large data analysis on clinical management. Wreesmann VB, Oomen KP, Brennan PA.J Oral Pathol Med. 2022 Nov;51(10):904-910. Current classification of vascular anomalies of the head and neck. Oomen KPQ, Wreesmann VB. J Oral Pathol Med. 2022 Nov;51(10):830-836. A novel classification of carotid body tumors.Wreesmann VB, Nixon IJ. Eur. J. Surg. Oncol. May, 2021 Management of the contralateral central neck in differentiated thyroid cancer: A contentious issue. Shaha AR, Tuttle RM, Wreesmann VB. Eur. J. Surg. Oncol. 2021 Apr;47(4):717-719. Improvement of oral cancer screening quality and reach: The promise of artificial intelligence. Kar A, Wreesmann VB, Shwetha V, Thakur S, Rao VUS, Arakeri G, Brennan PA.J Oral Pathol Med. 2020 Mar 11 The risk-benefit ratio of chemoradiation treatment in head and neck squamous cell carcinoma: value of extranodal spread and margin status. Ammar M, Wreesmann VB. Journal of ENT Masterclass, Yearbook 2018, Volume 11, Nr. 1, December 1st, 2018 Nasal obstruction secondary to an inverted midline supernumerary tooth. Jones L, Hilton JM, Heyman J, Viswanathan H, Wreesmann VB, Hayes SM. Ann R Coll Surg Engl. 2019 Jan;101(1) Fanconi anemia and homologous recombination gene variants are associated with functional DNA repair defects in vitro and poor outcome in patients with advanced head and neck squamous cell carcinoma. Verhagen CVM, Vossen DM, Borgmann K, Hageman F, Grénman R, Verwijs-Janssen M, Mout L, Kluin RJC, Nieuwland M, Severson TM, Velds A, Kerkhoven R, O'Connor MJ, van der Heijden M, van Velthuysen ML, Verheij M, Wreesmann VB, Wessels LFA, van den Brekel MWM, Vens C. Oncotarget. 2018 Apr 6;9(26):18198-18213. Complete nasal obstruction secondary to pacemaker insertion. Jones TL, Wreesmann VB, Nilssen E, Hilton J, Hayes SM. Ann R Coll Surg Engl. 2018 May;100(5) Optimization of the risk-benefit ratio of differentiated thyroid cancer treatment. Nasef HO, Nixon IJ, Wreesmann VB. Eur J Surg Oncol. 2018 Mar;44(3):276-285. Review. The risk/benefit ratio of differentiated thyroid cancer treatment: Exploring treatment de-escalation. Wreesmann VB; on behalf of EJSO. Eur J Surg Oncol. 2018 Mar;44(3):275. Aggressive differentiated thyroid cancer. Janjua N, Wreesmann VB. Eur J Surg Oncol. 2018 Mar;44(3):367-377. Review. Role of extracapsular nodal spread and surgical margin status in defining high-risk head and neck squamous cell carcinoma and its treatment intensity. Wreesmann VB. International Journal of Head and Neck Surgery, April-June 2017; 8(2): 76-83. An International Multi-Institutional Validation of Age 55 Years as a Cutoff for Risk Stratification in the AJCC/UICC Staging System for Well-Differentiated Thyroid Cancer.              Nixon IJ, Wang LY, Migliacci JC, Eskander A, Campbell MJ, Aniss A, Morris L, Vaisman F, Corbo R, Momesso D, Vaisman M, Carvalho A, Learoyd D, Leslie WD, Nason RW, Kuk D, Wreesmann V, Morris L, Palmer FL, Ganly I, Patel SG, Singh B, Tuttle RM, Shaha AR, Gönen M, Pathak KA, Shen WT, Sywak M, Kowalski L, Freeman J, Perrier N, Shah JP. Thyroid. 2016 Mar;26(3):373-80. Influence of extracapsular nodal spread extent on prognosis of oral squamous cell carcinoma.  Wreesmann VB, Katabi N, Palmer FL, Montero PH, Migliacci JC, Gönen M, Carlson D, Ganly I, Shah JP, Ghossein R, Patel SG.Head Neck. 2016 Apr;38 Suppl 1:E1192-9. Defining a Valid Age Cutoff in Staging of Well-Differentiated Thyroid Cancer. Nixon IJ, Kuk D, Wreesmann V, Morris L, Palmer FL, Ganly I, Patel SG, Singh B, Tuttle RM, Shaha AR, Gönen M, Shah JP. Ann Surg Oncol. 2015 Jul 28. Prognostic value of vascular invasion in well-differentiated papillary thyroid carcinoma. Wreesmann VB, Nixon IJ, Rivera M, Katabi N, Palmer F, Ganly I, Shaha AR, Tuttle RM, Shah JP, Patel SG, Ghossein RA.Thyroid. 2015 May;25(5):503-8. Head and neck squamous cell carcinoma in young patients.van Monsjou HS, Wreesmann VB, van den Brekel MW, Balm AJ. Oral Oncol. 2013 Dec;49(12):1097-102. Oral and oropharyngeal squamous cell carcinomas in young patients: The Netherlands Cancer Institute experience. van Monsjou HS, M Lopez-Yurda, M. Hauptmann, Balm AJ, van den Brekel MM, Wreesmann VB. Head Neck. 2013 Jan;35(1):94-102. Oropharyngeal squamous cell carcinoma: a unique disease on the rise?van Monsjou HS, Balm AJ, van den Brekel MM, Wreesmann VB. Oral Oncol. 2010 Nov;46(11):780-5. Closure of tracheoesophageal fistula with prefabricated revascularized bilaminar radial forearm free flap.Wreesmann VB, Smeele LE, Hilgers FJ, Lohuis PJ. Head Neck. 2009 Jun;31(6):838-42. Clinical impact of molecular analysis on thyroid cancer management.Wreesmann VB, Singh B. Surg Oncol Clin N Am. 2008 Jan;17(1):1-35. Genetic abnormalities associated with chemoradiation resistance of head and neck squamous cell carcinoma. van den Broek GB, Wreesmann VB, van den Brekel MW, Rasch CR, Balm AJ, Rao PH. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4386-91. Association of CD44 V3-containing isoforms with tumor cell growth, migration, matrix metalloproteinase expression, and lymph node metastasis in head and neck cancer.Wang SJ, Wreesmann VB, Bourguignon LY. Head Neck. 2007 Jun;29(6):550-8. Downregulation of Fanconi anemia genes in sporadic head and neck squamous cell carcinoma. Wreesmann VB, Estilo C, Eisele DW, Singh B, Wang SJ.ORL J Otorhinolaryngol Relat Spec. 2007;69(4):218-25. Epub 2007 Apr 4. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression. Saltman B, Singh B, Hedvat CV, Wreesmann VB, Ghossein R. Surgery. 2006 Dec;140(6):899-905; discussion 905-6. Repetitive endoscopic sinus surgery failure: a role for radical surgery?Videler WJ, Wreesmann VB, van der Meulen FW, Knegt PP, Fokkens WJ. Otolaryngol Head Neck Surg. 2006 Apr;134(4):586-91. MUC1 plays a role in tumor maintenance in aggressive thyroid carcinomas. Patel KN, Maghami E, Wreesmann VB, Shaha AR, Shah JP, Ghossein R, Singh B. Surgery. 2005 Dec;138(6):994-1001; discussion 1001-2. Chromosomal aberrations in squamous cell carcinomas of the upper aerodigestive tract: biologic insights and clinical opportunities.Wreesmann VB, Singh B. J Oral Pathol Med. 2005 Sep;34(8):449-59. Review. Molecular profiling of tumor progression in head and neck cancer. Belbin TJ, Singh B, Smith RV, Socci ND, Wreesmann VB, Sanchez-Carbayo M, Masterson J, Patel S, Cordon-Cardo C, Prystowsky MB, Childs G. Arch Otolaryngol Head Neck Surg. 2005 Jan;131(1):10-8. Identification of novel prognosticators of outcome in squamous cell carcinoma of the head and neck.Wreesmann VB, Shi W, Thaler HT, Poluri A, Kraus DH, Pfister D, Shaha AR, Shah JP, Rao PH, Singh B. J Clin Oncol. 2004 Oct 1;22(19):3965-72. Follicular variant of papillary thyroid carcinoma: genome-wide appraisal of a controversial entity.Wreesmann VB, Ghossein RA, Hezel M, Banerjee D, Shaha AR, Tuttle RM, Shah JP, Rao PH, Singh B. Genes Chromosomes Cancer. 2004 Aug;40(4):355-64. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker.Wreesmann VB, Sieczka EM, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky M, Shaha AR, Kraus D, Shah JP, Rao PH, Ghossein R, Singh B.  Cancer Res. 2004 Jun 1;64(11):3780-9. Genetic abnormalities associated with nodal metastasis in head and neck cancer.Wreesmann VB, Wang D, Goberdhan A, Prasad M, Ngai I, Schnaser EA, Sacks PG, Singh B. Head Neck. 2004 Jan;26(1):10-5. Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. Kutler DI, Wreesmann VB, Goberdhan A, Ben-Porat L, Satagopan J, Ngai I, Huvos AG, Giampietro P, Levran O, Pujara K, Diotti R, Carlson D, Huryn LA, Auerbach AD, Singh B. J Natl Cancer Inst. 2003 Nov 19;95(22):1718-21. Chromosomal aberrations in patients with head and neck squamous cell carcinoma do not vary based on severity of tobacco/alcohol exposure.Singh B, Wreesmann VB, Pfister D, Poluri A, Shaha AR, Kraus D, Shah JP, Rao PH. BMC Genet. 2002 Nov 14;3:22. Epub 2002 Nov 14. Genome-wide appraisal of thyroid cancer progression. Wreesmann VB, Ghossein RA, Patel SG, Harris CP, Schnaser EA, Shaha AR, Tuttle RM, Shah JP, Rao PH, Singh B. Am J Pathol. 2002 Nov;161(5):1549-56. Refractory chronic sinusitis: evaluation of symptom improvement after Denker’s procedure. Wreesmann VB, Fokkens WJ, Knegt PP. Otolaryngol Head Neck Surg. 2001 Nov;125(5):495-500. Inflammatory pseudotumour (inflammatory myofibroblastic tumour) of the pancreas: a report of six cases associated with obliterative phlebitis. Wreesmann V, van Eijck CH, Naus DC, van Velthuysen ML, Jeekel J, Mooi WJ. Histopathology. 2001 Feb;38(2):105-10. Screening for genetic aberrations in papillary thyroid cancer by using comparative genomic hybridization. Singh B, Lim D, Cigudosa JC, Ghossein R, Shaha AR, Poluri A, Wreesmann VB, Tuttle M, Shah JP, Rao PH. Surgery. 2000 Dec;128(6):888-93;discussion 893-4. Abstracts (Presentations at scientific meetings): Genome-wide screening for genetic prognostic factors in papillary thyroid carcinoma. Wreesmann VB, Ghossein RA, Poluri A, Shaha AR, Tuttle RM, Shah JP Rao PH, Singh B.Fifth International Conference on Head and Neck Cancer San Francisco, CA, July 2000. Hierarchical Clustering (HC): a Novel Approach to Evaluating the Prognostic Value of Laboratory Parameters in Patients (Pts) Undergoing Chemoradiation Treatment (CRT) for Advanced Laryngopharyngeal Carcinoma (LPC). Singh B, Pfister D, Wreesmann VB, Li R, Gogineni S, Bosl G, Hoffman RH, Shah JP, Rao PH. 37th Annual Meeting of the American Society of Clinical Oncology; New Orleans LA, May 2001. Gain of 1q is unique to the tall cell variant of papillary thyroid cancer.Wreesmann VB, Ghossein RA, Tuttle RM, Shaha AR, Robbins R, Shah JP, Rao PH, Singh B. 73rd annual meeting of the American Thyroid Association, Washington D.C. November 2001. MUC1 is a target of 1q amplification and pertains a grave clinical prognosis in papillary thyroid cancer. Wreesmann VB, Sieczka E, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Shah JP, Rao PH, Ghossein RG, Singh B. Annual Meeting of the New York Head and Neck Society, New York, NY, March 2002. Genome wide screening identified gains and losses as independent prognostic variables in patients with head and neck squamous cell carcinoma (HNSCC). Singh B, Wreesmann VB, Thaler HT, Shi W, Shah JP, Shaha AR, Kraus DH, Boyle JO, Pfister D, Rao PH. 38th Annual Meeting of the American Society of Clinical Oncology; Orlando, Fl May 2002. p53 inactivation by human papillomavirus (HPV) in Fanconi anemia associated squamous cell carcinoma. Kutler DI, Goberdhan A, Wreesmann VB, Giampietro PF, Auerbach AD, Singh B. The Sixth Research Workshop on the Biology, Prevention, and Treatment of Head and Neck Cancer; Washington D.C.; October 2002. Identification of novel prognostic factors in head and neck squamous cell carcinoma.  Wreesmann VB, Shi W, Thaler HT, Shah JP, Shaha AR, Kraus DH, Boyle JO, Pfister D, Rao PH, Singh B. 7th symposion on Research in Head and Neck Cancer; Dusseldorf, Germany, September 4-6 2003. Molecular profiling of aggressive papillary thyroid cancer: prognostic significance of MUC1 alterations. Wreesmann VB, Sieczka E, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky M, Shaha AR, Kraus D, Shah JP, Rao PH, Ghossein RA, Singh B. 7th symposion on Research in Head and Neck Cancer; Dusseldorf, Germany, September 4-6 2003. Chromosomal aberrations in Fanconi anemia-associated squamous cell carcinomas differ from sporadic squamous cell carcinomas from the general population. Kutler DI, Rao PH, Wreesmann VB, Goberdhan A, Ngai I, Huvos AG, Giampietro PF, Levran O, Pujara K, Diotti R, Auerbach AD, Singh B. 15th annual Fanconi Anemia Research Fund scientific symposium, Houston TX, Oct 2003. Molecular classification of Fanconi anemia(FA)-associated head and neck squamous cell carcinoma (HNSCC) using oligonucleotide microarrays. Kutler DI, Ganly I, Wreesmann VB, Goberdhan A, Ngai I, Huvos AG, Giampietro PF, Levran O, Pujara K, Diotti R, Auerbach AD, Singh B. 15th annual Fanconi Anemia Research Fund scientific symposium, Houston TX, Oct 2003. Genotyping follicular cell-derived thyroid neoplasia: a CGH study of 150 cases.Wreesmann VB, Ghossein RA, Socci N, Shaha AR, Tuttle RM, Shah JP, Rao PH, Singh B. Sixth International Conference on Head and Neck Cancer, Washington DC, August 2004. Downregulation of Fanconi anemia genes in sporadic squamous cell carcinomas of the head and neck. Wreesmann VB, Estilo C, Eisele DW, Singh B, Wang SJ. 208th meeting of the Netherlands Society of Otolaryngology-Head and Neck Surgery, Utrecht, April 7th 2006. Extracapsular nodal spread does not predict outcome in clinically node negative oral cavity squamous cell carcinoma. Wreesmann VB, Ghossein RA, Carlson D, Ganly I, Palmer F, Montero P, Shah JP, Patel SG. AHNS 2013 Annual Meeting, April 10 & 11, 2013, Orlando Florida. Minor (<2mm) extracapsular spread is not an adverse predictor of outcome in metastatic squamous cell carcinoma of the oral cavity. Wreesmann VB, Ghossein RA, Carlson D, Ganly I, Palmer F, Montero P, Shah JP, Patel SG. Presented at the AHNS 2014 Annual Meeting, July 2014, New York, New York. Books, Chapters: Molecular Biology as applied to Head and Neck OncologyWreesmann VB, Singh B.Stell and Maran's Textbook of Head and Neck Surgery and OncologyFifth EditionChapter, edited by John Watkinson and Ralph Gilbert Molecular-Cytogenetic Characterization of Head and Neck Cancer: Identification of molecular prognostic factors and targets of therapyWreesmann VB, Singh B.Book, Amsterdam 2004Reviewed in: Head and Neck: Volume 29, Issue 1, pages 82–83, January 2007 Open Conservation Surgery for Laryngeal CancerWreesmann VB, Ganly IScott-Brown's Otorhinolaryngology and Head and Neck Surgery, Eighth EditionChapter 27CRC Press, Taylor-Francis Group, June 12th, 2018 Molecular OncologyWreesmann V.B.Self-Assessment in Head and Neck Surgery and Oncology, First EditionChapter 21Elsevier 2014 Research grants:Netherlands Cancer Institute “Startgeld” Grant 2008Project: Fanconi anemia in head and neck cancerPrincipal investigators: Wreesmann VB, van den Brekel MW, Balm AJM, Vens C.Amount granted: 300.000 euro